SCHEMBL31227273

SCHEMBL31227273

Cn1nnc(-c2ccc(C(=O)Cl)cc2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
TP53 P04637 4/20 0.42
NPC1 O15118 3/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
USP2 O75604 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
ALOX15 P16050 1/20 0.41
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
RECQL P46063 1/20 0.40
TSHR P16473 2/20 0.40
HSD17B10 Q99714 2/20 0.40
LMNA P02545 2/20 0.40
GAA P10253 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3087490 0.84 LMNA (0.54) RAB9ASMN1; SMN2TP53NPC1NFKB1
SCHEMBL4927936 0.83 MKNK1 (0.44) RAB9ASMN1; SMN2TP53NPC1NFKB1
SCHEMBL5321983 0.80 SMN1; SMN2 (0.51) SMN1; SMN2TP53TSHRHSD17B10GAA
SCHEMBL6872550 0.80 LMNA (0.61) RAB9ASMN1; SMN2TP53NPC1USP2
SCHEMBL5058907 0.79 ALDH1A1 (0.42) RAB9ASMN1; SMN2TP53NPC1USP2
SCHEMBL2611134 0.78 KMT2A (0.54) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL851750 0.78 NPC1 (0.52) RAB9ASMN1; SMN2TP53NPC1NFKB1
SCHEMBL2644715 0.78 SMN1; SMN2 (0.46) RAB9ASMN1; SMN2TP53NPC1NFKB1
SCHEMBL5775 0.76 LTA4H (0.51) RAB9ASMN1; SMN2TP53NPC1NFKB1
SCHEMBL13841588 0.76 NPC1 (0.54) RAB9ASMN1; SMN2NPC1NFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors INITIAL THERAPEUTICS, INC. (US) 2024-12-05 US disclosed
WO-2024226875-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS INITIAL THERAPEUTICS, INC. (US) 2024-10-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors MYCBP, MYC, MYCBP2 RAB9A 3390/4885SMN1; SMN2 3533/4885TP53 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.